Primary study · included by 1 review

Makarenko 2024

ProbableThe reviews cited this study without a PMID, DOI or NCT, so it is matched by first author and year. Two different studies by the same author in the same year could be merged here.

Included by

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Non-Cochrane · prognostic · 2026 · cited as Makarenko 2024 · Reference list; Fig. 1-3
Outcome this study informsPooled effectEvidenceCertainty
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · within 2 months after RIT
Prevalence 0.60 [0.28, 0.85]3 studies · 1502 participantsGRADE not reported
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · between 2 and 6 months after RIT
Prevalence 0.37 [0.28, 0.47]4 studies · 392 participantsGRADE not reported

1 including review in total.